Publications by authors named "Melhem Solh"

Claim this Profile
G
Genomics of Acute Myeloid Leukemia at Diagnosis and Remission.
Kai Yu, Laura W Dillon, Jesse M Tettero, Gege Gui, Rasha W Al-Ali, Melhem Solh

medRxiv· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia.
Timothy E O'Connor, Chenyu Lin, Gregory W Roloff, Amy Zhang, Katharine Miller, Melhem M Solh

Bone Marrow Transplant· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of transplant conditioning, NPM1 mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemia.
Mark J Levis, Mehdi Hamadani, Brent R Logan, Richard J Jones, Anurag K Singh, Melhem Solh

Blood Adv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD19 CAR T-Cell Therapy for Primary Mediastinal Large B-Cell Lymphoma: A CIBMTR Analysis.
Jordan Gauthier, Kwang W Ahn, Jinalben Patel, Qinghua Lian, Sherif Badawy, Melhem Solh

Am J Hematol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia.
Yannis K Valtis, Chenyu Lin, David Nemirovsky, Sean M Devlin, Kai Rejeski, Melhem M Solh

Blood Adv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of brexucabtagene autoleucel in patients with relapsed/refractory acute lymphoblastic leukemia with CNS involvement.
Ibrahim N Muhsen, Gregory W Roloff, Rawan Faramand, Tamer Othman, Yannis Valtis, Melhem M Solh

Blood Adv· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of posttransplant cyclophosphamide-based GVHD prophylaxis in patients 70 years and older: an update from BMT CTN 1703.
Sameem Abedin, Michael J Martens, Javier Bolaños-Meade, Monzr M Al Malki, Qinghua Lian, Melhem Solh

Blood Adv· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML.
Mark J Levis, Mehdi Hamadani, Brent R Logan, Richard J Jones, Anurag K Singh, Melhem Solh

Blood· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703.
Shernan G Holtan, Javier Bolaños-Meade, Monzr M Al Malki, Juan Wu, Carrie L Kitko, Melhem M Solh

J Clin Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Haploidentical Bone Marrow Transplantation for Sickle Cell Disease.
Adetola A Kassim, Mark C Walters, Mary Eapen, Madoc Smith, Brent R Logan, Melhem Solh

NEJM Evid· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL.
Gregory W Roloff, Ibrahim Aldoss, Noam E Kopmar, Chenyu Lin, Simone E Dekker, Melhem M Solh

J Clin Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Loncastuximab tesirine in previously treated diffuse large B-cell lymphoma: A plain language summary of the LOTIS-2 study.
Mehdi Hamadani, Paolo F Caimi, Brian Hess, John Radford, Melhem Solh

Future Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of patients with primary central nervous system lymphoma following CD19-targeted chimeric antigen receptor T-cell therapy.
Santiago Mercadal, Kwang Woo Ahn, Mariam Allbee-Johnson, Siddhartha Ganguly, Praveen Ramakrishnan Geethakumari, Melhem Solh

Haematologica· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL.
Ibrahim Aldoss, Gregory W Roloff, Rawan Faramand, Noam E Kopmar, Chenyu Lin, Melhem M Solh

Blood Adv· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intrathecal chemotherapy as treatment for chimeric antigen receptor T cell (CAR T) therapy associated neurotoxicity.
Saffiya Z Bashey, Scott R Solomon, Xu Zhang, Lawrence E Morris, H Kent Holland, Melhem M Solh

Bone Marrow Transplant· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HLA evolutionary divergence (HED) informs the effect of HLA-B mismatch on outcomes after haploidentical transplantation.
Melhem Solh, Michael T Aubrey, Xu Zhang, Asad Bashey, Brian M Freed

Bone Marrow Transplant· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Graft-Versus-Host Disease on Relapse and Nonrelapse Mortality Following Posttransplant Cyclophosphamide-Based Transplantation.
Scott R Solomon, Lizamarie Bachier-Rodriguez, Asad Bashey, Xu Zhang, Katelin C Jackson, Melhem M Solh

Transplant Cell Ther· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study.
Tania Jain, Noel Estrada-Merly, M Queralt Salas, Soyoung Kim, Jakob DeVos, Melhem Solh

Blood Adv· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunosuppression-Free Status at 1 Year after Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide.
Melhem Solh, Asad Bashey, Xu Zhang, H Kent Holland, Lizamarie Bachier-Rdriguez

Transplant Cell Ther· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Revised HLA-DP TCE-Core Permissiveness Model Better Defines Relapse Risk and Survival following Haploidentical Transplant.
Scott R Solomon, Michael T Aubrey, Lizamarie Bachier-Rodriguez, Melhem M Solh, Katelin C Jackson

Transplant Cell Ther· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of .
Mark J Levis, Mehdi Hamadani, Brent Logan, Richard J Jones, Anurag K Singh, Melhem Solh

J Clin Oncol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Letermovir prophylaxis lowers the incidence of Non-CMV infections after allogeneic hematopoietic cell transplantation.
Saffiya Z Bashey, Scott R Solomon, Xu Zhang, Lawrence E Morris, H Kent Holland, Melhem M Solh

Bone Marrow Transplant· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical Trial.
Juan Pablo Alderuccio, Isildinha M Reis, Mehdi Hamadani, Muthiah Nachiappan, Salman Leslom, Melhem Solh

Clin Cancer Res· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial.
Mehdi Hamadani, Alexander Spira, Xiaolei Zhou, Laura Liao, Lei Chen, Melhem Solh

Blood Adv· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial.
Nizar J Bahlis, Caitlin L Costello, Noopur S Raje, Moshe Y Levy, Bhagirathbhai Dholaria, Melhem Solh

Nat Med· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis